[Helicobacter pylori eradication: modified triple therapy with lansoprazole]

Area of Science:

• Gastroenterology
• Pharmacology
• Microbiology

Background:

• Helicobacter pylori (H.p.) infection is a primary cause of peptic ulcer disease.
• Modified triple therapy, combining an acid suppressant with two antibiotics, is the preferred H.p. eradication treatment.
• Proton pump inhibitors (PPIs) are key components of H.p. eradication regimens.

Purpose of the Study:

• To evaluate the efficacy of lansoprazole as a component of modified triple therapy for H.p. eradication.
• To assess the effectiveness and tolerability of a 7-day lansoprazole-based triple therapy regimen.
• To compare the cost-effectiveness of lansoprazole versus omeprazole in H.p. eradication.

Main Methods:

• Systematic review of 12 studies involving over 600 H.p.-positive peptic ulcer patients.
• Analysis of eradication rates using lansoprazole in combination with clarithromycin and metronidazole or amoxicillin and clarithromycin.
• Evaluation of treatment duration, tolerability, and patient compliance.

Main Results:

• Lansoprazole-based triple therapy achieved consistently high H.p. eradication rates exceeding 85%.
• A 7-day treatment duration was sufficient for successful eradication.
• The regimen demonstrated good tolerability and patient-friendliness.

Conclusions:

• Lansoprazole is an effective and well-tolerated agent for H.p. eradication in peptic ulcer patients.
• The 7-day lansoprazole-based modified triple therapy offers a cost-effective alternative to omeprazole.
• This regimen presents a valuable option for managing H.p. infections and peptic ulcer disease.